1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ
LENZ Therapeutics, Inc.US flagNASDAQ Global Select
5.96
USD
+0.13
- -
186.87MMarket Cap
LENZ Therapeutics, Inc.
LENZ
(NASDAQ Global Select)

Recent

price

5.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
0.59
- -
- -
0.66
0.7
Revenue per Share
-0.3
-0.42
-2.74
-2.34
-2.85
-4.12
Basic EPS, GAAP
-0.21
-0.16
-2.37
-2.81
-2.43
-3.74
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.56
-0.95
-3.63
7.42
9.07
6.99
Book Value per Share
-0.56
-0.95
-3.63
7.42
9.07
6.99
Tangible Book Value per Share
26
26
26
21
29
31
Basic Weighted Avg Shares
- -
15
- -
- -
19
21
Sales/Revenue/Turnover
- -
-69.89
- -
- -
-477.46
-631.7
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
-8
-11
-70
-50
-82
-126
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-72.07
- -
- -
-430.25
-586.74
Profit Margin (%)
17
37
49
202
280
216
Working Capital
- -
- -
- -
1
- -
- -
LT Debt
-14
-24
-93
204
284
219
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-33.63
-59.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
502
287
178

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
301
268
233
Cash, Cash Equivalents & STI
292
258
220
Accounts Receivable, Net
- -
- -
- -
Inventories
3
3
4
Total Current Liabilities
21
26
17
Payables & Accruals
21
25
16
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
39.32%
Free Cash Flow
- -
- -
16.94%
Net Income, GAAP
- -
- -
65.02%
Sales/Revenue/Turnover
- -
- -
27.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
5
12
2
19
2026
2
5
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.53
-0.4
-0.38
-0.46
-2.34
2025
-0.53
-0.53
-0.59
-1.16
-2.85
2026
-1.32
-1.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Seer, Inc. (SEER)
Nanoform Finland Oyj (NANOFH.HE)
Kineta, Inc. (KA)
Sol-Gel Technologies Ltd. (SLGL)
ARS Pharmaceuticals, Inc. (SPRY)
Humacyte, Inc. (HUMAW)
Business
LENZ Therapeutics, Inc. is a pharmaceutical company concentrating on advancing and making available treatments to enhance sight. Its flagship product, VIZZ™ (aceclidine ophthalmic solution) 1.44%, has received U.S. FDA approval for the correction of near vision in adults experiencing presbyopia. This once-daily eye drop operates as a pupil-selective miotic, creating a pinhole effect to sharpen close-up vision for up to ten hours while minimally affecting distance vision. The company has initiated the commercial launch of VIZZ™ in the United States and has established exclusive licensing and commercialization agreements for LNZ100 in territories such as Canada, Korea, and Southeast Asia. LENZ Therapeutics is based in Solana Beach, California.

Company News

Company News APIChatGPT

  • seekingalpha.com

    LENZ Therapeutics: Still Speculative But Priced For Disasters

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

  • defenseworld.net

    Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. $LENZ

  • seekingalpha.com

    LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    LENZ Therapeutics Q2 Earnings Call Highlights

  • zacks.com

    LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

  • globenewswire.com

    LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • globenewswire.com

    LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

  • zacks.com

    Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline

  • globenewswire.com

    LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

  • globenewswire.com

    LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

  • proactiveinvestors.com

    LENZ Therapeutics adds China partner for presbyopia drug VIZZ

  • globenewswire.com

    LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

  • globenewswire.com

    LENZ Therapeutics to Participate in Upcoming Investor Conferences

  • 247wallst.com

    Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More

  • seekingalpha.com

    LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript

  • marketbeat.com

    LENZ Therapeutics Q1 Earnings Call Highlights

  • zacks.com

    LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

  • globenewswire.com

    LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights